KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Equity Average (2018 - 2026)

Aquestive Therapeutics has reported Equity Average over the past 8 years, most recently at -$18.9 million for Q4 2025.

  • For Q4 2025, Equity Average rose 64.22% year-over-year to -$18.9 million; the TTM value through Dec 2025 reached -$18.9 million, up 64.22%, while the annual FY2025 figure was -$46.9 million, 43.7% up from the prior year.
  • Equity Average for Q4 2025 was -$18.9 million at Aquestive Therapeutics, up from -$38.3 million in the prior quarter.
  • Over five years, Equity Average peaked at -$18.9 million in Q4 2025 and troughed at -$113.9 million in Q1 2023.
  • A 5-year average of -$72.3 million and a median of -$69.0 million in 2021 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: tumbled 272.14% in 2021 and later soared 66.75% in 2024.
  • Year by year, Equity Average stood at -$71.2 million in 2021, then plummeted by 58.88% to -$113.2 million in 2022, then grew by 7.49% to -$104.7 million in 2023, then soared by 49.59% to -$52.8 million in 2024, then skyrocketed by 64.22% to -$18.9 million in 2025.
  • Business Quant data shows Equity Average for AQST at -$18.9 million in Q4 2025, -$38.3 million in Q3 2025, and -$66.8 million in Q2 2025.